209 related articles for article (PubMed ID: 34585227)
1. Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force.
Kaye J; Aisen P; Amariglio R; Au R; Ballard C; Carrillo M; Fillit H; Iwatsubo T; Jimenez-Maggiora G; Lovestone S; Natanegara F; Papp K; Soto ME; Weiner M; Vellas B
J Prev Alzheimers Dis; 2021; 8(4):513-519. PubMed ID: 34585227
[TBL] [Abstract][Full Text] [Related]
2. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
[TBL] [Abstract][Full Text] [Related]
3. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
Aisen P; Touchon J; Amariglio R; Andrieu S; Bateman R; Breitner J; Donohue M; Dunn B; Doody R; Fox N; Gauthier S; Grundman M; Hendrix S; Ho C; Isaac M; Raman R; Rosenberg P; Schindler R; Schneider L; Sperling R; Tariot P; Welsh-Bohmer K; Weiner M; Vellas B
J Prev Alzheimers Dis; 2017; 4(2):116-124. PubMed ID: 29186281
[TBL] [Abstract][Full Text] [Related]
4. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.
Bateman RJ; Blennow K; Doody R; Hendrix S; Lovestone S; Salloway S; Schindler R; Weiner M; Zetterberg H; Aisen P; Vellas B
J Prev Alzheimers Dis; 2019; 6(3):169-173. PubMed ID: 31062827
[TBL] [Abstract][Full Text] [Related]
5. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.
Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B
J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788
[TBL] [Abstract][Full Text] [Related]
6. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force.
Angioni D; Delrieu J; Hansson O; Fillit H; Aisen P; Cummings J; Sims JR; Braunstein JB; Sabbagh M; Bittner T; Pontecorvo M; Bozeat S; Dage JL; Largent E; Mattke S; Correa O; Gutierrez Robledo LM; Baldivieso V; Willis DR; Atri A; Bateman RJ; Ousset PJ; Vellas B; Weiner M
J Prev Alzheimers Dis; 2022; 9(4):569-579. PubMed ID: 36281661
[TBL] [Abstract][Full Text] [Related]
7. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
Cummings J; Fox N; Vellas B; Aisen P; Shan G
J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
[TBL] [Abstract][Full Text] [Related]
8. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.
Aisen PS; Siemers E; Michelson D; Salloway S; Sampaio C; Carrillo MC; Sperling R; Doody R; Scheltens P; Bateman R; Weiner M; Vellas B
J Prev Alzheimers Dis; 2018; 5(3):171-174. PubMed ID: 29972209
[TBL] [Abstract][Full Text] [Related]
9. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
[TBL] [Abstract][Full Text] [Related]
10. Prevention trials in Alzheimer's disease: an EU-US task force report.
Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
[TBL] [Abstract][Full Text] [Related]
11. Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report.
Raman R; Aisen PS; Carillo MC; Detke M; Grill JD; Okonkwo OC; Rivera-Mindt M; Sabbagh M; Vellas B; Weiner M; Sperling R
J Prev Alzheimers Dis; 2022; 9(3):388-392. PubMed ID: 35841239
[TBL] [Abstract][Full Text] [Related]
12. Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.
Vellas B; Bateman R; Blennow K; Frisoni G; Johnson K; Katz R; Langbaum J; Marson D; Sperling R; Wessels A; Salloway S; Doody R; Aisen P;
J Prev Alzheimers Dis; 2015 Jun; 2(2):128-135. PubMed ID: 26247004
[TBL] [Abstract][Full Text] [Related]
13. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.
Sano M; Soto M; Carrillo M; Cummings J; Hendrix S; Mintzer J; Porsteinsson A; Rosenberg P; Schneider L; Touchon J; Aisen P; Vellas B; Lyketsos C
J Prev Alzheimers Dis; 2018; 5(2):98-102. PubMed ID: 29616702
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.
Vellas B; Hampel H; Rougé-Bugat ME; Grundman M; Andrieu S; Abu-Shakra S; Bateman R; Berman R; Black R; Carrillo M; Donohue M; Mintun M; Morris J; Petersen R; Thomas RG; Suhy J; Schneider L; Seely L; Tariot P; Touchon J; Weiner M; Sampaio C; Aisen P;
J Nutr Health Aging; 2012 Apr; 16(4):339-45. PubMed ID: 22499454
[TBL] [Abstract][Full Text] [Related]
15. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.
Aisen P; Touchon J; Andrieu S; Boada M; Doody R; Nosheny RL; Langbaum JB; Schneider L; Hendrix S; Wilcock G; Molinuevo JL; Ritchie C; Ousset PJ; Cummings J; Sperling R; DeKosky ST; Lovestone S; Hampel H; Petersen R; Legrand V; Egan M; Randolph C; Salloway S; Weiner M; Vellas B
J Prev Alzheimers Dis; 2016; 3(2):68-74. PubMed ID: 29210442
[TBL] [Abstract][Full Text] [Related]
16. Commentary: Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
Siemers E
J Prev Alzheimers Dis; 2019; 6(3):180-181. PubMed ID: 31062831
[No Abstract] [Full Text] [Related]
17. Digital endpoints in clinical trials of Alzheimer's disease and other neurodegenerative diseases: challenges and opportunities.
Brem AK; Kuruppu S; de Boer C; Muurling M; Diaz-Ponce A; Gove D; Curcic J; Pilotto A; Ng WF; Cummins N; Malzbender K; Nies VJM; Erdemli G; Graeber J; Narayan VA; Rochester L; Maetzler W; Aarsland D
Front Neurol; 2023; 14():1210974. PubMed ID: 37435159
[TBL] [Abstract][Full Text] [Related]
18. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
[TBL] [Abstract][Full Text] [Related]
19. Designing pharmaceutical trials for sarcopenia in frail older adults: EU/US Task Force recommendations.
Vellas B; Pahor M; Manini T; Rooks D; Guralnik JM; Morley J; Studenski S; Evans W; Asbrand C; Fariello R; Pereira S; Rolland Y; Abellan van Kan G; Cesari M; Chumlea WC; Fielding R
J Nutr Health Aging; 2013 Jul; 17(7):612-8. PubMed ID: 23933872
[TBL] [Abstract][Full Text] [Related]
20. Task force on Alzheimer's disease trial methodology: recruitment and retention, data management and analysis. The use of imaging in recruitment: maintenance and methodological issues in Alzheimer's trials.
Suhy J
J Nutr Health Aging; 2012 Apr; 16(4):349-51. PubMed ID: 22499456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
